VitalTransformation

05/05/2025

Small‑molecule therapies face Medicare price negotiations four years sooner than biologics. That disparity, known as the “pill penalty,” has already shifted early‑stage investors away from small‑molecule research. This especially impacts investments into drugs developed for indications affecting primarily seniors.

A new PhRMA blog by Brianna Allen cites our peer‑reviewed finding: early‑stage funding for small molecules has plunged nearly 70%.

- Affordable pills are disappearing.
- At‑home dosing is at risk.
- Critical therapies are being cut.

🔗 Read the full PhRMA article: https://buff.ly/1mGUHHS

We Work For Health

05/02/2025

Our new research shows the IRA’s “pill penalty” is changing small-molecule R&D investment:

- By mid-2024, aggregate funding for large-molecule lead assets was 10 times that for small molecules, which plunged 68% post-IRA.
- Small molecules targeting indications above the 59% Medicare‐exposure median saw a 74% drop in median investment size (p ≤ 0.0018); no such decline for low-exposure assets.
- Early-stage clinical trial launches fell 35% after IRA’s passage (p ≤ 0.0179), yet large-molecule investments remain statistically unchanged by Medicare exposure.

Small molecules with low Medicare exposure saw no funding dip, highlighting how the IRA specifically disincentivizes drugs seniors rely on. Aligning small-molecule pricing with biologics (13-year window) could boost Medicare-targeted approvals by 21%.

🔗 Read the full study: https://buff.ly/CrTmhOr

We Work For Health

05/01/2025

“The IRA makes most early-stage, small molecule drug development projects for diseases of aging uninvestable.” -Richard Xie

Medicare’s nine-year price-setting deadline for chemically synthesized pills—four years sooner than for protein-based biologics—upends the basic economics of funding new oral therapies. Financial models that discount every future dollar back to today reveal that chopping off profits after Year 9 erodes almost half the project’s value before it even reaches human trials.

Unsurprisingly, investors are pivoting away from small-molecule programs in Alzheimer’s, Parkinson’s, diabetes, and other conditions that predominantly affect seniors. They’re reallocating capital toward biologics, whose price negotiations don’t begin until Year 13—or toward rare diseases and platform technologies that skirt Medicare’s “pill penalty.” In a world where every percentage point in expected returns matters, these shifts aren’t optional—they’re survival.

If we want treatments for aging populations to remain on the table, policymakers must realign incentives. Extending the small-molecule negotiation window to match biologics at thirteen years would restore the financial runway innovators need to bring life-saving oral therapies across the finish line.

Read more from Richard Xie: https://buff.ly/4w5EV5P

We Work For Health

04/30/2025

On April 15, President Trump issued a new executive order aimed at revising Medicare’s drug pricing policies, explicitly calling to eliminate the “pill penalty” that subjects small-molecule drugs to government price setting four years earlier than biologics. As the order notes: “This discrepancy threatens to distort innovation by pushing investment towards expensive biological products... and away from small molecule prescription drugs, which are generally cheaper and treat larger patient populations.”

Our latest peer-reviewed research helps explain why this change is needed. In a study of 161 early-stage therapies, we found that small-molecule drugs aimed at conditions with high Medicare exposure saw their median investment size drop from $175 million to just $45 million following the IRA’s passage.

The new order seeks to reverse this trend, realigning incentives to ensure investment returns to the kinds of therapies millions of seniors depend on: https://buff.ly/5oFWhrA

04/29/2025

The Inflation Reduction Act empowers Medicare to set “maximum fair prices” for small-molecule drugs, which are chemically synthesized pills and tablets, rather than large, protein-based biologics. Small molecules typically treat common conditions, but under the IRA, they face price controls just nine years after approval (compared to 13 years for biologics), shortening the period of market exclusivity and creating a “pill penalty” by cutting off the later years of sales and eroding investors’ expected returns.

In a new case study measuring net present value (NPV), a financial method that converts future profits into today’s dollars, Richard Z. Xie, Tess Cameron, and Peter Kolchinsky modeled a representative launch curve based on Entresto, a small-molecule heart-failure therapy chosen for its typical sales trajectory and high Medicare exposure. They found that under the IRA’s nine-year negotiation, which effectively caps U.S. reimbursement at the maximum fair price, projected profits beyond Year 9 fall to zero. That change slashes project NPV by ~40%, and the model predicts the program would not advance beyond the Phase I decision point.

Our peer-reviewed research on 161 early-stage lead assets (619 individual investments) finds that small-molecule therapies targeting indications with above-median exposure to the Medicare-aged population saw median investment size plunge from $175 million to $45 million (a 74% drop) after the IRA took effect (p ≤ 0.0018).

Together, these analyses show that the IRA’s shorter pricing window for pills is discouraging investment in essential, affordable therapies. Policymakers should extend the small-molecule negotiation window to thirteen years, matching biologics and ensuring developers have time to recoup R&D costs and keep life-saving treatments on the horizon.

Read Xie et al.'s (2025) report here:

The impact of Medicare’s price negotiation on long-term pharmaceutical innovation and patient welfare remains one of the most widely debated topics across stakeholder groups. Existing policy simulations have tried to assess the policy impacts on innovation based on either empirical estimates of el...

04/28/2025

Reuters reporter Ahmed Aboulenein recently covered a new executive order by the Trump administration aiming to revise Medicare’s drug price negotiation timeline - a shift pharma companies have long pushed for.

Our latest peer-reviewed study shows why this matters: small molecule therapies, which face price setting sooner under the IRA, have seen a 74% drop in early-stage investment, particularly for diseases that primarily impact seniors.

When policy shortens the return window, investment moves elsewhere. And the consequences show in the data.

🔗 Reuters: https://buff.ly/gcqHOI5
🔗 VT research: https://buff.ly/CrTmhOr

04/27/2025

Imagine standing by a river, watching water rush along its course. Picture placing massive boulders in that flow, intending to slow and reshape the current. The water still runs, but it diverts around each obstacle, inadvertently carving new paths downstream.

That’s exactly what the Inflation Reduction Act (IRA) did to drug development; by capping price negotiations at year nine for small molecules and year 13 for biologics, it felt like a way to lower costs, but the "boulders" inevitably diverted investment away from the most accessible pills, especially those seniors depend on. Suddenly, early-stage researchers find their path blocked, and fewer small-molecule treatments are making it to market.

We sat down with Steve Usdin to unpack how the IRA shifts R&D incentives and what it means for future therapies. Other topics discussed include biopharma tariffs, NIH/FDA budget cuts, post-COVID science skepticism, and China’s surge in clinical filings.

Listen to the full conversation here: https://buff.ly/9ZuZR3K

We Work For Health

04/26/2025

Although the IRA was sold as a measure to cap drug costs, its core effect was to rewrite the period of guaranteed price protection for new therapies.

Small-molecule drugs now enter Medicare’s price-setting after 9 years, while large-molecule biologics retain 13 years of protected pricing under the same framework. This change in exclusivity windows has a major impact on which drugs receive critical R&D funding.

Price exclusivity allows developers to recoup the billions spent on research, clinical trials, and manufacturing scale-up. Although lower prices sound appealing, it shrinks the period during which companies can recover costs and fund new R&D, meaning that cheaper medicines today come at the expense of discovering tomorrow’s treatments. Early-stage investors rely on those protected years to justify the high risk of backing novel molecules.

When one class of treatment enjoys 4 additional years of guaranteed returns, our research demonstrates that early-stage investors shift capital toward complex biologics and away from traditional pills (especially ones with indications for the Medicare-age population). This limits the range of medicines that make it to market. Steve Usdin highlights how this outcome was never intended. Listen to the full conversation here: https://buff.ly/9ZuZR3K

We Work For Health

04/25/2025

Steve Usdin just laid out how pharma lobbyists are racing to fix the IRA’s “pill penalty” (which forces price controls on pills four years sooner than on biologics).

We found the impact firsthand - our study of 161 early-stage drugs shows median funding for senior-focused pills tumbled from $175 M to $45 M after the IRA passed.

To dig deeper, we sat down with Steve on the VT podcast, where we also unpack looming drug-specific tariff probes, NIH/FDA budget cuts, post-COVID science skepticism, and China’s surge in clinical filings. We Work For Health

Read Usdin's BioCentury article: https://buff.ly/L3GWSOo
Hear the full conversation: https://buff.ly/9ZuZR3K

Biopharma lobbyists, who suffered an epic defeat when the Medicare drug price negotiation provisions were included in the Inflation Reduction Act, celebrat...

04/25/2025

Early-stage clinical trials by small biotech companies dropped 35% after the Inflation Reduction Act (IRA), signaling a sharp slowdown in drug development.

Between 2018 and 2021, trial launches by U.S. companies valued at $2 billion or less were steadily increasing. These weren’t large pharmaceutical firms—they were small and mid-sized developers advancing early innovation, often focused on high-need areas like oncology and rare diseases. That upward trend halted abruptly after the IRA was introduced in September 2021.

The orange line in the figure shows actual monthly clinical trial activity for 1,100 Phase I and II trials. The gray dashed line represents where that trend was headed before the policy shift. The gap between them reflects a real behavioral change among early-stage investors and developers. Statistical testing confirms this decline is meaningful (p ≤ 0.0179).

This analysis is part of our new study examining how the IRA has changed the calculus for venture capital and startups. We focused on each company's lead asset—their most advanced drug in development—and linked clinical trial launches to real financial activity across 619 investments. By limiting the analysis to companies below $2B in value, we homed in on where IRA incentives would be felt first.

Clinical trials don’t just appear. They represent years of scientific work and financial risk. And a sustained drop like this points to longer-term consequences for patients, especially those relying on small molecule therapies that are now less attractive to investors due to the IRA’s shorter commercial window.

Full study: https://buff.ly/SWgBSFl

We Work For Health